Terazosin Hydrochloride Tablets

This product is a selective α1 receptor blocker that can reduce peripheral vascular resistance and has a lowering effect on both systolic and diastolic blood pressure; it has the effect of relaxing bladder and prostate smooth muscles and can relieve symptoms of dysuria caused by benign prostatic hypertrophy.

The main ingredient of this product is: terazosin hydrochloride. Its chemical name is: 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydrofuran-2-formyl)piperazine, monohydrochloride dihydrate.

This product is white tablets.

1. Used to treat hypertension, and can be used alone or in combination with other antihypertensive drugs. 2. Used to improve urination symptoms in patients with benign prostatic hyperplasia, such as frequent urination, urgency, thinning of the urine stream, difficulty urinating, increased nocturia, and a feeling of incomplete urination.

Oral. Hypertensive patients: once a day, first before bedtime. The starting dose is 1 mg, and the dose is gradually increased until a satisfactory effect is achieved. The common dose is 1-10 mg a day, and the maximum dose is 20 mg a day. If treatment needs to be restarted after discontinuation of the drug, the dose must also be gradually increased from 1 mg. Patients with benign prostatic hyperplasia: once a day, 2 mg each time, before bedtime every night.

The main adverse reactions of this product are: headache, dizziness, weakness, palpitations, nausea, postural hypotension, etc. These reactions are usually mild and will disappear on their own with continued treatment. The dosage can be reduced if necessary.

It is contraindicated for those who are allergic to this product.

Precautions for children: Not clear. Precautions for pregnancy and lactation: Pregnant women are prohibited from using this product. Lactating women should stop breastfeeding when using this product. Precautions for the elderly: Pharmacokinetic studies have shown that the recommended dose does not need to be changed when the elderly use this product. Elderly patients are more likely to develop orthostatic hypotension than younger patients when using terazosin to treat benign prostatic hyperplasia.

In clinical trials, the proportion of patients who reported dizziness or other related adverse reactions in patients treated with this product and angiotensin (ACE) inhibitors or diuretics was higher than the proportion of all patients treated with this product. When this product is used in combination with other antihypertensive drugs, care should be taken to avoid significant hypotension. When this product is added to diuretics or other antihypertensive drugs, the dose should be reduced and re-formulated if necessary. It is known that this product does not interact with analgesics/anti-inflammatory drugs, cardiac glycosides, hypoglycemic drugs, antiarrhythmic drugs, antianxiety drugs/sedatives, antibacterial drugs, hormones/steroids and gout treatment drugs.

Keep away from light and store in a sealed container.

1 mg (calculated as C19H25N504HCl)

24 months

Suzhou Dawnrays Pharmaceutical Co., Ltd.

• Founded in:

  1995-12-08

• Address:

  No. 268, Minfeng Road, Wuzhong Economic Development Zone, Suzhou

• Tax NO.:

  913205006283933800

• Registered Funds:

  $131.5 million

• Website:

  Log in to view

• Email:

  Log in to view